MASLD is a new term for metabolic dysfunction-associated fatty liver disease, characterized by hepatic steatosis in the presence of one or more cardio-metabolic risk factors such as obesity, type 2 diabetes, or dyslipidemia.[5] It affects approximately 38% of the world's population and is predicted to increase to 55% by 2040, with a higher prevalence in obese and diabetic individuals.[5] MASLD has become a major cause of cirrhosis and hepatocellular carcinoma and is recognized as both a hepatic and systemic disease associated with cardiovascular, renal, and endocrine comorbidities.[5] Despite its increasing importance, MASLD remains underdiagnosed.[5] The report calls for a structured multidisciplinary approach with an emphasis on liver risk stratification in obesity.[1][5] Among the prognostic factors, the stage of fibrosis is the most reliable predictor of outcomes including mortality.[5] Lifestyle changes are the mainstay of treatment, with resmetir and semaglutide being the first FDA-approved drugs to modify liver disease in patients with moderate to advanced fibrosis.[5] Noninvasive tools serve for diagnosis and staging, although they have clinical limits.[5]